P21

Status Not approved for human use; no verifiable identity established in the sources reviewedBest evidence E5Sources checked 2026-09-18

P21 is sold as a BDNF-mimetic, TrkB-agonist research peptide. No PubMed-indexed primary research paper or registered trial describing a compound under this name was located for this entry, and the name collides with the unrelated cell-cycle protein p21 (CDKN1A), which dominates search results.

What this entry can and cannot say

Vendor and forum material describes “P21” as a brain-derived neurotrophic factor (BDNF) mimetic peptide, sometimes described as a partial TrkB receptor agonist intended to cross the blood-brain barrier and support memory, mood and neuroprotection. No PubMed-indexed primary research paper describing a compound named P21 or P021 with that identity, sequence or mechanism was located in the searches run for this entry, and no registered human or animal trial under that name was found on ClinicalTrials.gov.

The name itself is a further complication. “P21” is also the common short name for p21 (CDKN1A), a well-studied cell-cycle regulatory protein with an enormous, unrelated scientific literature; this collision makes the compound circulating under this name difficult to search for and impossible to distinguish from that literature using the name alone.

This entry exists to record that gap honestly rather than to describe a mechanism this site cannot verify. If a specific manufacturer, sequence or primary paper for the compound sold as “P21” becomes identifiable, this entry will be rewritten around it.

What is not known

Whether a peptide matching the vendor description of P21 has been studied in any published, indexed research, in any species.

The compound’s actual amino acid sequence, molecular identity, or relationship (if any) to published BDNF-mimetic or TrkB-agonist peptide research from other named compounds.

Any human or animal safety, pharmacokinetic or efficacy data whatsoever.

What is not known

Whether a peptide matching the vendor description of P21 has been studied in any published, indexed research, in any species.

The compound’s actual amino acid sequence or molecular identity.

Any human or animal safety, pharmacokinetic or efficacy data whatsoever.

Whether “P21” as sold is related to, or entirely distinct from, other named BDNF-mimetic or TrkB-agonist compounds described in the peer-reviewed literature under different names.

Doses used in published research

No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.

Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.

Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported use	Route	Amount reported	Frequency	Reported length
Cognitive/neuroprotective support, general	Subcutaneous	Varies by listing	Varies by listing	Varies by listing

Circulating dosing for P21 varies between listings and cannot be checked against a studied human or animal dose, because no primary research under this name was located for this entry at all. A dose figure with nothing behind it to compare against is not a data point.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.